8-K Announcements
6Material company update
Jun 2, 2026·SEC
Material company update
May 21, 2026·SEC
Material company update
Jan 23, 2026·SEC
PetMed Express, Inc.(PETS)Earnings, Financials & Key Ratios
PETS•NASDAQ
$1.92
Price updated Jul 7, 2026
AboutPetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, and other pet supplies. It sells its products through its Internet website; mobile app; telephone contact center; and direct mail/print, which includes brochures and postcards, as well as television advertising under the 1-800-PetMeds and PetMeds brands. PetMed Express, Inc. was incorporated in 1996 and is headquartered in Delray Beach, Florida.Show more
- Revenue$179M-21.1%
- EBITDA-$22M-499.9%
- Net Income-$57M-813.5%
- EPS (Diluted)-2.74-813.3%
- Gross Margin28.05%-7.9%
- EBITDA Margin-12.3%-607.0%
- Operating Margin-17.55%-2503.2%
- Net Margin-32%-1058.2%
- ROE-100.44%-1356.4%
PETS Price & Volume
PetMed Express, Inc. (PETS) stock price & volume — 10-year historical chart
Loading chart...
Persistent Revenue Contraction Threatens Operational Solvency
Investment Thesis • Updated 2026Q4
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and customer churn
Key Thesis Takeaways
- PetMed Express faces a critical inflection point as its legacy transactional model struggles to compete against integrated e-commerce platforms, resulting in a 21.13% year-over-year revenue decline.
- The company's inability to scale fixed costs has pushed operating margins to -13.3% as of 2026Q4, while the rapid erosion of retained earnings from $71.6M to $9.3M over two years signals significant long-term value destruction.
- Investors should remain cautious as the current liquidity buffer of $21.4M appears insufficient to support the firm's ongoing operational burn rate and potential restructuring needs.
Verdict Logic
the company's inability to maintain profitability, evidenced by a -9.5% net margin in 2026Q4, combined with a shrinking asset base, suggests high risk for equity holders.
PETS Growth Metrics
PetMed Express, Inc. (PETS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-2.67%
5 Years-10.02%
3 Years-11.31%
TTM-21.13%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-813.51%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-803.71%
Return on Capital
10 Years13.39%
5 Years-7.95%
3 Years-20.96%
Last Year-54.59%
PETS Recent Earnings
PetMed Express, Inc. (PETS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (17%)●Beat Revenue 2/12 qtrs (17%)
Q3 2026Latest
Jun 2, 2026Metric
Actual
Est
EPS
$0.19-5.6%
$0.18
Rev
$43M-17.7%
$52M
Q1 2026
Feb 5, 2026Metric
Actual
Est
EPS
$0.50-733.3%
$0.06
Rev
$41M-24.8%
$54M
Q4 2025
Dec 19, 2025Metric
Actual
Est
EPS
$0.34-1600.0%
$0.02
Rev
$44M-36.0%
$69M
Q1 2025
Feb 10, 2025Metric
Actual
Est
EPS
$0.03-700.0%
$0.01
Rev
$53M-1.9%
$54M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2026Latest | Jun 2, 2026 | $0.19vs $0.18-5.6% | $43Mvs $52M-17.7% |
| Q1 2026 | Feb 5, 2026 | $0.50vs $0.06-733.3% | $41Mvs $54M-24.8% |
| Q4 2025 | Dec 19, 2025 | $0.34vs $0.02-1600.0% | $44Mvs $69M-36.0% |
| Q1 2025 | Feb 10, 2025 | $0.03vs $0.01-700.0% | $53Mvs $54M-1.9% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for PetMed Express, Inc. (PETS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.92 | $41.02M | -0.70 | -21.13% | -32% | -100.44% | 0.05% | |
| $20.73 | $8.58B | 39.87 | 6.24% | 1.57% | 44.82% | — | |
| $2.53 | $722.48M | 79.81 | -2.53% | -0.39% | -2.03% | — | |
| $54.51 | $2.68B | 20.65 | 13.01% | 17.63% | 16.98% | — | |
| $36.17 | $7.94B | 70.92 | 59% | -0.56% | -2.48% | — | |
| $9.10 | $1.64B | -7.98 | -1.54% | -6.81% | -12.37% | — |
Compare PETS vs Peers
PetMed Express, Inc. (PETS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PETS SEC Filings & Documents
PetMed Express, Inc. (PETS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when PETS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PETS Frequently Asked Questions
PetMed Express, Inc. (PETS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is PetMed Express, Inc.'s revenue?
PetMed Express, Inc. (PETS) reported $179.0M in revenue for fiscal year 2026. This represents a 1120% increase from $14.7M in 2000.
How fast is PetMed Express, Inc. growing?
PetMed Express, Inc. (PETS) saw revenue decline by 21.1% over the past year.
Is PETS profitable?
PetMed Express, Inc. (PETS) reported a net loss of $57.3M for fiscal year 2026.
Dividend & Returns
Does PETS pay dividends?
PetMed Express, Inc. (PETS) does not currently pay a meaningful dividend. The company may be reinvesting profits for growth.
What is PETS's return on equity?
PetMed Express, Inc. (PETS) has a return on equity (ROE) of -100.4%. Negative ROE indicates the company is unprofitable.
What is PetMed Express, Inc.'s free cash flow?
PetMed Express, Inc. (PETS) had negative free cash flow of $33.0M in fiscal year 2026, likely due to heavy capital investments.